News & Press
Grant aids drug discovery for autism, schizophrenia
Grant aids drug discovery for autism, schizophrenia
With the aid of a four-year, $2.7 million grant from the National Institute of Mental Health, part of the National Institutes of Health (NIH), Vanderbilt University Medical Center pharmacologist Jerod Denton, PhD, and his team will pave the way for potential treatments for schizophrenia and autism spectrum disorder (ASD).
CAS Life Sciences Advisory Board
WCNDD Executive Director, Craig Lindsley, joins CAS Life Sciences Advisory Board. The board will guide the expanded CAS drug discovery journey to empower better decisions early in the drug discovery process. Read full press release at CAS convenes life sciences advisory board to reimagine the future of scientific discovery | CAS.
Discoveries in Medicine - Vanderbilt Health Update
More on our ongoing collaboration with W. David Merryman, Walters Family Professor of Biomedical Engineering at VU, on addressing pulmonary arterial hypertension (PAH) using peripherally restricted 5-HT2B antagonists.
Lindsley named 2022 fellow of American Society for Pharmacology and Experimental Therapeutics
Craig W. Lindsley, University Distinguished Professor of Pharmacology, Biochemistry and Chemistry, who holds the William K. Warren, Jr. Chair in Medicine, was recently announced as a 2022 fellow of the American Society for Pharmacology and Experimental Therapeutics for his demonstrated excellence and contributions to pharmacology and to the ASPET organization.